Is ECOR or CARL more profitable?

electroCore has a net margin of -44.08% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -44.08% -1,956.38% -83.30% Carlsmed -57.76% -60.74% -29.84%

electroCore (ECOR) Competitors

$8.79 +0.49 (+5.90%)

Closing price 03:59 PM Eastern

Extended Trading

$8.77 -0.02 (-0.23%)

As of 04:10 PM Eastern

Compare

ECOR vs. CARL, TMCI, TLSI, OBIO, and PROF

Should you buy electroCore stock or one of its competitors? MarketBeat compares electroCore with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with electroCore include Carlsmed (CARL), Treace Medical Concepts (TMCI), TriSalus Life Sciences (TLSI), Orchestra BioMed (OBIO), and Profound Medical (PROF). These companies are all part of the "medical equipment" industry.

How does electroCore compare to Carlsmed?

electroCore (NASDAQ:ECOR) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

electroCore presently has a consensus price target of $18.00, indicating a potential upside of 104.78%. Carlsmed has a consensus price target of $18.75, indicating a potential upside of 64.84%. Given electroCore's higher possible upside, analysts plainly believe electroCore is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

electroCore has higher earnings, but lower revenue than Carlsmed. electroCore is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$34.90M	2.09	-$13.97M	-$1.77	N/A
Carlsmed	$50.51M	6.12	-$29.63M	-$2.51	N/A

26.7% of electroCore shares are owned by institutional investors. 13.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

electroCore has a net margin of -44.08% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Carlsmed	-57.76%	-60.74%	-29.84%

In the previous week, Carlsmed had 2 more articles in the media than electroCore. MarketBeat recorded 3 mentions for Carlsmed and 1 mentions for electroCore. electroCore's average media sentiment score of 1.89 beat Carlsmed's score of 0.96 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Very Positive
Carlsmed	Positive

Summary

Carlsmed beats electroCore on 8 of the 15 factors compared between the two stocks.

How does electroCore compare to Treace Medical Concepts?

electroCore (NASDAQ:ECOR) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

electroCore has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Treace Medical Concepts has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

In the previous week, Treace Medical Concepts had 1 more articles in the media than electroCore. MarketBeat recorded 2 mentions for Treace Medical Concepts and 1 mentions for electroCore. electroCore's average media sentiment score of 1.89 beat Treace Medical Concepts' score of 1.24 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Very Positive
Treace Medical Concepts	Positive

Treace Medical Concepts has a net margin of -29.44% compared to electroCore's net margin of -44.08%. Treace Medical Concepts' return on equity of -67.04% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Treace Medical Concepts	-29.44%	-67.04%	-30.28%

electroCore currently has a consensus target price of $18.00, indicating a potential upside of 104.78%. Treace Medical Concepts has a consensus target price of $4.77, indicating a potential upside of 12.90%. Given electroCore's stronger consensus rating and higher probable upside, equities analysts clearly believe electroCore is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

26.7% of electroCore shares are owned by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are owned by institutional investors. 13.8% of electroCore shares are owned by company insiders. Comparatively, 23.4% of Treace Medical Concepts shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

electroCore has higher earnings, but lower revenue than Treace Medical Concepts. electroCore is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$34.90M	2.09	-$13.97M	-$1.77	N/A
Treace Medical Concepts	$212.69M	1.29	-$59M	-$0.97	N/A

Summary

Treace Medical Concepts beats electroCore on 10 of the 15 factors compared between the two stocks.

How does electroCore compare to TriSalus Life Sciences?

electroCore (NASDAQ:ECOR) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, TriSalus Life Sciences had 1 more articles in the media than electroCore. MarketBeat recorded 2 mentions for TriSalus Life Sciences and 1 mentions for electroCore. electroCore's average media sentiment score of 1.89 beat TriSalus Life Sciences' score of 0.89 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Very Positive
TriSalus Life Sciences	Positive

electroCore has a net margin of -44.08% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

electroCore has higher earnings, but lower revenue than TriSalus Life Sciences. electroCore is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$34.90M	2.09	-$13.97M	-$1.77	N/A
TriSalus Life Sciences	$45.15M	6.39	-$39.23M	-$1.41	N/A

electroCore presently has a consensus price target of $18.00, indicating a potential upside of 104.78%. TriSalus Life Sciences has a consensus price target of $7.50, indicating a potential upside of 59.78%. Given electroCore's higher probable upside, equities research analysts plainly believe electroCore is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

electroCore has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

26.7% of electroCore shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 13.8% of electroCore shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

TriSalus Life Sciences beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to Orchestra BioMed?

electroCore (NASDAQ:ECOR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

In the previous week, Orchestra BioMed had 2 more articles in the media than electroCore. MarketBeat recorded 3 mentions for Orchestra BioMed and 1 mentions for electroCore. electroCore's average media sentiment score of 1.89 beat Orchestra BioMed's score of 0.62 indicating that electroCore is being referred to more favorably in the media.

Company	Overall Sentiment
electroCore	Very Positive
Orchestra BioMed	Positive

electroCore has a net margin of -44.08% compared to Orchestra BioMed's net margin of -166.96%. Orchestra BioMed's return on equity of -157.46% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

electroCore currently has a consensus target price of $18.00, indicating a potential upside of 104.78%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 222.66%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than electroCore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

electroCore has higher revenue and earnings than Orchestra BioMed. electroCore is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$34.90M	2.09	-$13.97M	-$1.77	N/A
Orchestra BioMed	$33.48M	7.54	-$52.70M	-$0.97	N/A

electroCore has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

26.7% of electroCore shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 13.8% of electroCore shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Orchestra BioMed beats electroCore on 10 of the 16 factors compared between the two stocks.

How does electroCore compare to Profound Medical?

Profound Medical (NASDAQ:PROF) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 26.7% of electroCore shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 13.8% of electroCore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Profound Medical had 1 more articles in the media than electroCore. MarketBeat recorded 2 mentions for Profound Medical and 1 mentions for electroCore. electroCore's average media sentiment score of 1.89 beat Profound Medical's score of 0.93 indicating that electroCore is being referred to more favorably in the news media.

Company	Overall Sentiment
Profound Medical	Positive
electroCore	Very Positive

electroCore has a net margin of -44.08% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
electroCore	-44.08%	-1,956.38%	-83.30%

electroCore has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	15.47	-$42.57M	-$1.24	N/A
electroCore	$34.90M	2.09	-$13.97M	-$1.77	N/A

Profound Medical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, electroCore has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Profound Medical presently has a consensus price target of $12.00, indicating a potential upside of 75.08%. electroCore has a consensus price target of $18.00, indicating a potential upside of 104.78%. Given electroCore's higher probable upside, analysts clearly believe electroCore is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

electroCore beats Profound Medical on 8 of the 14 factors compared between the two stocks.

Get electroCore News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ECOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ECOR vs. The Competition

Export

Metric	electroCore	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$72.92M	$3.08B	$6.94B	$12.39B
Dividend Yield	N/A	1.93%	2.67%	6.14%
P/E Ratio	-4.97	20.02	27.70	24.92
Price / Sales	2.09	360.78	538.45	99.66
Price / Cash	N/A	57.40	47.99	59.26
Price / Book	-41.86	4.32	10.91	6.47
Net Income	-$13.97M	$64.45M	$3.57B	$336.81M
7 Day Performance	22.25%	5.01%	3.59%	2.52%
1 Month Performance	-6.98%	5.23%	4.38%	0.27%
1 Year Performance	63.99%	30.18%	35.74%	25.61%

electroCore Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ECOR electroCore	3.8827 of 5 stars	$8.79 +5.9%	$18.00 +104.8%	+58.4%	$72.92M	$34.90M	N/A	50	Positive News Gap Up
CARL Carlsmed	3.1914 of 5 stars	$10.69 +8.6%	$19.33 +80.9%	N/A	$267.50M	$50.51M	N/A	100	Analyst Forecast
TMCI Treace Medical Concepts	2.5946 of 5 stars	$4.49 +12.0%	$4.77 +6.2%	-29.7%	$260.14M	$212.69M	N/A	250	Positive News
TLSI TriSalus Life Sciences	3.1055 of 5 stars	$4.03 -4.0%	$7.50 +86.1%	-13.4%	$257.95M	$45.15M	N/A	106
OBIO Orchestra BioMed	4.0059 of 5 stars	$4.04 -1.0%	$13.60 +236.6%	+55.2%	$244.31M	$32.72M	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ECOR) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

electroCore (ECOR) Competitors

ECOR vs. CARL, TMCI, TLSI, OBIO, and PROF

How does electroCore compare to Carlsmed?

Summary

How does electroCore compare to Treace Medical Concepts?

Summary

How does electroCore compare to TriSalus Life Sciences?

Summary

How does electroCore compare to Orchestra BioMed?

Summary

How does electroCore compare to Profound Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ECOR vs. The Competition

electroCore Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

electroCore (ECOR) Competitors

ECOR vs. CARL, TMCI, TLSI, OBIO, and PROF

How does electroCore compare to Carlsmed?

Do analysts prefer ECOR or CARL?

Which has better earnings & valuation, ECOR or CARL?

Do institutionals & insiders believe in ECOR or CARL?

Is ECOR or CARL more profitable?

Does the media prefer ECOR or CARL?

Summary

How does electroCore compare to Treace Medical Concepts?

Which has more volatility & risk, ECOR or TMCI?

Does the media prefer ECOR or TMCI?

Is ECOR or TMCI more profitable?

Do analysts rate ECOR or TMCI?

Do insiders & institutionals believe in ECOR or TMCI?

Which has higher valuation & earnings, ECOR or TMCI?

Summary

How does electroCore compare to TriSalus Life Sciences?

Does the media favor ECOR or TLSI?

Is ECOR or TLSI more profitable?

Which has preferable earnings and valuation, ECOR or TLSI?

Do analysts rate ECOR or TLSI?

Which has more risk and volatility, ECOR or TLSI?

Do insiders and institutionals believe in ECOR or TLSI?

Summary

How does electroCore compare to Orchestra BioMed?

Does the media favor ECOR or OBIO?

Is ECOR or OBIO more profitable?

Do analysts rate ECOR or OBIO?

Which has better valuation and earnings, ECOR or OBIO?

Which has more risk & volatility, ECOR or OBIO?

Do institutionals & insiders believe in ECOR or OBIO?

Summary

How does electroCore compare to Profound Medical?

Do insiders & institutionals have more ownership in PROF or ECOR?

Does the media refer more to PROF or ECOR?

Is PROF or ECOR more profitable?

Which has preferable valuation & earnings, PROF or ECOR?

Which has more volatility & risk, PROF or ECOR?

Do analysts rate PROF or ECOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ECOR vs. The Competition

electroCore Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools